Autologous antibodies that bind neuroblastoma cells
Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Nov;426:35-41; PMID:26210205
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler G, A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma, Pediatr Blood Cancer. 2016 Jan;63(1):39-46. doi: [...]
Autologous antibodies that bind neuroblastoma cells
Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Jul 23. pii: S0022-1759(15)30025-9. doi: 10.1016/j.jim.2015.07.009. [Epub ahead of print]
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Saulnier Sholler G, Gerner EW, Bergendahl G, MacArthur RB, Vander Werff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya S, Bachmann AS, A Phase I Trial of DFMO Targeting Polyamine Addiction in [...]
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed [...]
YM155 Inhibits Neuroblastoma Cell Migration and Survival in Vitro and Tumor Growth and Metastatic Burden in a Pre-Clinical Model
Calderone HM., Dutta A, Smith L, Eckardt A, Zhao P, Saulnier Sholler GL, YM155 Inhibits Neuroblastoma Cell Migration and Survival in Vitro and Tumor Growth and Metastatic Burden in a Pre-Clinical Model. Journal of Cancer Therapy, Nov 2014 online: http://www.scirp.org/journal/jct
Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma
Lozier AM, Rich ME, Grawe AP, Peck AS, Zhao P, Ting-Tung Chang, Bond JP, Saulnier Sholler G, Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget 6(1): 196-206 (2014)
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma
Saulnier Sholler G, Currier E, Dutta A, Slavik M, Illenye S, Mendonca MC, Dragon J, Roberts S, Bond JP, PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. J Cancer Ther Res 2014 (accepted)
Mentoring in pediatric oncology: a report from the Children’s Oncology Group Young Investigator Committee
Levy AS1, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM J Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. Pediatr Hematol Oncol. 2013 Aug;35(6):456-61.
Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors
Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr Blood Cancer. 2013 Aug 17. doi: 10.1002/pbc.24656. [Epub ahead of print]